What makes this setback funny is that Aspen assured investors that it had designed the AppyScore clinical trial to specifically avoid such data collection problems. Remember, Aspen blamed disappointing results from a previous AppyScore study in part on poor data collection and patients lost to follow up.
Perhaps, AspenBio needs to come up with a new excuse for why AppyScore under-performs.
Unfortunately, Joe, I don't have a good guess for the length of this delay. My gut tells me that the AppyScore results, when they do emerge, will not be strong enough to turn AppyScore into a compelling commercial diagnostic product. That's been my
stance on AspenBio for awhile now and last week's news only reinforces my bearish sentiment.
More on Biotech
13 Drugs Facing FDA Approval Decisions
I'm on vacation all next week. Mailbag will return on July 2.-- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV